Circulating tumor DNA (ctDNA) sequencing for HER2 mutation (HER2mut) screening and response monitoring to neratinib in metastatic breast cancer (MBC)

被引：0
|
作者：
Ma, Cynthia
Bose, Ron
Gao, Feng
Freedman, Rachel
Telli, Melinda
Kimmick, Gretchen
Winer, Eric
Naughton, Michael
Goetz, Matthew
Russell, Christy
Tripathy, Debu
Cobleigh, Melody
Forero, Andres
Pluard, Timothy
Anders, Carey
Thomas, Shana
Anderson, Jill
Bumb, Caroline
Banks, Kimberly
Lanman, Richard
Bryce, Richard
Lalani, Alshad
Pfeifer, John
Hays, Daniel
Pegram, Mark
Blackwell, Kimberly
Bedard, Philippe
Al-Kateb, Hussam
Ellis, Matthew
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-CT011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT011
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Serum HER2 in the context of circulating tumor cells in patients with metastatic breast cancer.
    Mueller, Volkmar
    Riethdorf, Sabine
    Rack, Brigitte Kathrin
    Janni, Wolfgang
    Fasching, Peter A.
    Solomayer, Erich
    Aktas, Bahriye
    Kasimir-Bauer, Sabine
    Pantel, Klaus
    Fehm, Tanja N.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] ESTIMATING SCENARIOS FOR SURVIVAL TIME IN PATIENTS WITH HER2 POSITIVE, METASTATIC BREAST CANCER (MBC) STARTING HER2 TARGETED THERAPIES
    Vasista, A.
    Stockler, M.
    West, T.
    Wilcken, N.
    Kiely, B.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 44 - 45
  • [33] Therapeutic options in HER2 positive metastatic breast cancer (MBC): An embarrassment of riches
    Efrat , Noa
    TUMOR BIOLOGY, 2012, 33 : 36 - 36
  • [34] HER2 status of circulating tumor cells in HER2-positive metastatic breast cancer patients: A valuable biomarker in anti-HER2 therapy
    Jiang, Z.
    Li, L.
    Liu, Y.
    Wang, T.
    Zhang, S.
    Yuan, Y.
    Bian, L.
    Liu, Q.
    Qi, F.
    CANCER RESEARCH, 2013, 73
  • [35] Peptidylarginine deiminase 3 modulates response to neratinib in HER2 positive breast cancer
    Romero-Perez, Ines
    Diaz-Rodriguez, Elena
    Sanchez-Diaz, Laura
    Montero, Juan Carlos
    Pandiella, Atanasio
    ONCOGENESIS, 2024, 13 (01):
  • [36] Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor
    Beije, Nick
    Onstenk, Wendy
    Kraan, Jaco
    Sieuwerts, Anieta M.
    Hamberg, Paul
    Dirix, Luc Y.
    Brouwer, Anja
    de Jongh, Felix E.
    Jager, Agnes
    Seynaeve, Caroline M.
    Van, Ngoc M.
    Foekens, John A.
    Martens, John W. M.
    Sleijfer, Stefan
    NEOPLASIA, 2016, 18 (11): : 647 - 653
  • [37] Efficacy and safety of neratinib and capecitabine in HER2 positive metastatic breast cancer: a systematic review
    Mokalu, E. Wilhelmina
    Sabran, M. Zuhriansyah
    Yossy, P.
    Rubismo, K. Yogasvara
    Zebua, A.
    Albert, N.
    Hasan, J. Irisha Xenia
    Kurniawan, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1393 - S1393
  • [38] Prospective evaluation of serum HER2 in comparison with HER2 expression on circulating tumor cells in metastatic breast cancer patients as part of the DETECT study
    Mueller, V.
    Riethdorf, S.
    Rack, B.
    Janni, W.
    Fasching, P.
    Gebauer, G.
    Solomayer, E.
    Aktas, B.
    Zeitz, J.
    Kasimir-Bauer, S.
    Fehm, T.
    ONKOLOGIE, 2010, 33 : 19 - 19
  • [39] Distribution and prognostic role of HER2 status of circulating tumor cells (CTCs) and tumor-derived extracellular vesicles (tdEVs) in HER2-metastatic breast cancer (MBC) patients (pts)
    Nicolo, E.
    Munoz-Arcos, L.
    D'Amico, P.
    Zhang, Y.
    Gerratana, L.
    Serafini, M.
    Pontolillo, L.
    Strickland, K.
    Manai, M.
    Davis, A. A.
    Donahue, J.
    Liu, H.
    Gradishar, W. J.
    Shah, A. N.
    Curigliano, G.
    Reduzzi, C.
    Cristofanilli, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S363 - S363
  • [40] OVERCOMING HER2/ESTROGEN RECEPTOR (ER) CROSSTALK: NERATINIB ± FULVESTRANT IN ER+HER2-MUTANT METASTATIC BREAST CANCER (MBC) IN THE PHASE II SUMMIT TRIAL.
    Beer, Hannah
    Cutler, Rich
    Piha-Paul, Sarina
    Saura, Cristina
    Lalani, Alshad
    Hyman, David
    ONCOLOGY NURSING FORUM, 2017, 44 (02)
12345